Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results

Heron Therapeutics (NASDAQ:HRTX) announced its earnings results on Tuesday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03), Zacks reports. The business had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same quarter in the prior year, the company posted ($0.17) earnings per share. Heron Therapeutics updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Heron Therapeutics Stock Performance

NASDAQ:HRTX traded down $0.05 during mid-day trading on Wednesday, hitting $1.23. 2,641,296 shares of the stock traded hands, compared to its average volume of 2,420,921. Heron Therapeutics has a 52 week low of $0.53 and a 52 week high of $3.93. The firm’s 50 day moving average is $1.86 and its two-hundred day moving average is $2.54.

Analyst Ratings Changes

Separately, Needham & Company LLC decreased their target price on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.